vTv Therapeutics Inc. financial data

Symbol
VTVT on Nasdaq
Location
High Point, NC
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 784% % 68%
Debt-to-equity 107% % -73%
Return On Equity -98% % 47%
Return On Assets -48% % -1.2%
Operating Margin -175382% % -7209%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $23,162,697 USD 1.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $17,000 USD -98%
Research and Development Expense $16,187,000 USD 41%
General and Administrative Expense $13,645,000 USD 0.74%
Operating Income (Loss) $29,815,000 USD -24%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $28,379,000 USD -26%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $23,470,000 USD -28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $98,504,000 USD 137%
Accounts Receivable, after Allowance for Credit Loss, Current $62,000 USD -39%
Other Assets, Current $112,000 USD
Assets, Current $99,456,000 USD 132%
Property, Plant and Equipment, Net $14,000 USD -72%
Operating Lease, Right-of-Use Asset $24,000 USD -85%
Assets $99,494,000 USD 131%
Accounts Payable, Current $939,000 USD -77%
Contract with Customer, Liability, Current $0 USD -100%
Liabilities, Current $10,163,000 USD 58%
Contract with Customer, Liability, Noncurrent $18,669,000 USD 0%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $28,951,000 USD 15%
Retained Earnings (Accumulated Deficit) $319,554,000 USD -7.9%
Stockholders' Equity Attributable to Parent $70,543,000 USD 370%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $70,543,000 USD 294%
Liabilities and Equity $99,494,000 USD 131%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,687,000 USD 22%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,687,000 USD -113%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $98,504,000 USD 137%
Deferred Tax Assets, Valuation Allowance $34,030,000 USD 17%
Deferred Tax Assets, Gross $34,030,000 USD 17%
Operating Lease, Liability $125,000 USD -58%
Depreciation $9,000 USD -59%
Lessee, Operating Lease, Liability, to be Paid $129,000 USD -60%
Property, Plant and Equipment, Gross $536,000 USD -11%
Operating Lease, Liability, Current $32,000 USD -82%
Lessee, Operating Lease, Liability, to be Paid, Year Two $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8,000 USD -76%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD
Deferred Tax Assets, Operating Loss Carryforwards $27,819,000 USD 17%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Share-based Payment Arrangement, Expense $3,575,000 USD 53%